Roche Holding will focus on research deals in programs such as Alzheimer's disease and diabetes to "constantly rejuvenate" its pipeline, CEO Severin Schwan said. "We would only look at smaller and medium-size acquisitions," Schwan said. "We would not go for big mega-mergers like you see happening in the industry. We would go where the science takes us."

Related Summaries